DK0813606T3 - Fremgangsmåde til rensning af rekombinante virusvektorer indeholdende et terapeutisk gen - Google Patents

Fremgangsmåde til rensning af rekombinante virusvektorer indeholdende et terapeutisk gen

Info

Publication number
DK0813606T3
DK0813606T3 DK96911282T DK96911282T DK0813606T3 DK 0813606 T3 DK0813606 T3 DK 0813606T3 DK 96911282 T DK96911282 T DK 96911282T DK 96911282 T DK96911282 T DK 96911282T DK 0813606 T3 DK0813606 T3 DK 0813606T3
Authority
DK
Denmark
Prior art keywords
recombinant virus
vectors containing
virus vectors
therapeutic gene
purifying recombinant
Prior art date
Application number
DK96911282T
Other languages
Danish (da)
English (en)
Inventor
Paul W Shabram
Bernard G Huyghe
Xiaodong Liu
H Michael Shepard
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Application granted granted Critical
Publication of DK0813606T3 publication Critical patent/DK0813606T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F265/00—Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group C08F20/00
    • C08F265/02—Macromolecular compounds obtained by polymerising monomers on to polymers of unsaturated monocarboxylic acids or derivatives thereof as defined in group C08F20/00 on to polymers of acids, salts or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D11/00—Inks
    • C09D11/02—Printing inks
    • C09D11/10—Printing inks based on artificial resins
    • C09D11/106—Printing inks based on artificial resins containing macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/803—Physical recovery methods, e.g. chromatography, grinding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK96911282T 1995-03-07 1996-03-06 Fremgangsmåde til rensning af rekombinante virusvektorer indeholdende et terapeutisk gen DK0813606T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/400,793 US5837520A (en) 1995-03-07 1995-03-07 Method of purification of viral vectors

Publications (1)

Publication Number Publication Date
DK0813606T3 true DK0813606T3 (da) 2006-10-02

Family

ID=23585038

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96911282T DK0813606T3 (da) 1995-03-07 1996-03-06 Fremgangsmåde til rensning af rekombinante virusvektorer indeholdende et terapeutisk gen

Country Status (12)

Country Link
US (1) US5837520A (fr)
EP (2) EP0813606B1 (fr)
JP (2) JP3858200B2 (fr)
AR (1) AR001177A1 (fr)
AT (1) ATE329045T1 (fr)
AU (1) AU5421396A (fr)
DE (1) DE69636217T2 (fr)
DK (1) DK0813606T3 (fr)
ES (1) ES2264801T3 (fr)
PT (1) PT813606E (fr)
WO (1) WO1996027677A2 (fr)
ZA (1) ZA961849B (fr)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0738319A4 (fr) * 1994-01-12 2000-03-29 Genetic Therapy Inc Purification de vecteurs retroviraux
FR2737730B1 (fr) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
WO1997008298A1 (fr) 1995-08-30 1997-03-06 Genzyme Corporation Purification d'adenovirus et de virus adeno-associe (aav) par voie chromatographique
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US6392069B2 (en) * 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
IL127692A0 (en) * 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
US6576133B2 (en) 1996-11-13 2003-06-10 Transgenomic, Inc Method and system for RNA analysis by matched ion polynucleotide chromatography
US6475388B1 (en) 1996-11-13 2002-11-05 Transgenomic, Inc. Method and system for RNA analysis by matched ion polynucleotide chromatography
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
WO1998022588A2 (fr) * 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. Procede ameliore pour production et purification de vecteurs d'adenovirus
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US20080261289A1 (en) * 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6177559B1 (en) 1998-04-24 2001-01-23 Transgenomic, Inc. Process for separation of polynucleotide fragments
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
DK1009808T3 (da) 1997-09-05 2013-01-21 Genzyme Corp Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
WO1999019464A1 (fr) * 1997-10-09 1999-04-22 Biogen, Inc. Baculovirus concentre par chromatographie et procedes
US6258264B1 (en) 1998-04-10 2001-07-10 Transgenomic, Inc. Non-polar media for polynucleotide separations
US6265168B1 (en) 1998-10-06 2001-07-24 Transgenomic, Inc. Apparatus and method for separating and purifying polynucleotides
IL139040A0 (en) 1998-04-22 2001-11-25 Genvec Inc Efficient purification of adenovirus
US6489305B1 (en) * 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
EP1930418B1 (fr) 1998-09-04 2015-04-08 Genzyme Corporation Procédés pour produire des préparations de vecteurs AAV recombinants de forte teneur dépourvues de virus assistants
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
NZ512504A (en) 1998-12-31 2004-01-30 Aventis Pharma Sa Method for separating viral particles
JP4802366B2 (ja) * 1999-02-22 2011-10-26 トランスジェン・ソシエテ・アノニム 精製ウイルス調製物の取得方法
DE19933719A1 (de) * 1999-07-19 2001-01-25 Medigene Ag Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung
US6464976B1 (en) 1999-09-07 2002-10-15 Canji, Inc. Methods and compositions for reducing immune response
US6316185B1 (en) 1999-09-29 2001-11-13 Mountain View Pharmaceuticals, Inc. Quantitation of viruses by light scattering
JP4684434B2 (ja) * 2000-02-16 2011-05-18 Ｊｓｒ株式会社 ウイルス濃縮用粒子、ウィルス濃縮用試薬、ウイルス濃縮方法およびウイルス検出方法
DE10010342A1 (de) * 2000-03-06 2001-09-20 Merck Patent Gmbh Verfahren zur Abreicherung von Endotoxinen
US6767699B2 (en) * 2000-05-31 2004-07-27 Chiron Corporation Method for the quantitation of alphavirus replicon particles
US6593123B1 (en) 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
US6447995B1 (en) 2000-10-04 2002-09-10 Genvec, Inc. Utilizing intrinsic fluorescence to detect adenovirus
US20020064860A1 (en) * 2000-11-29 2002-05-30 Schering Corporation Method for purifying adenoviruses
WO2002049422A2 (fr) * 2000-12-20 2002-06-27 K.U. Leuven Research And Development Modeles de maladies developpes chez des animaux non humains
KR100451308B1 (ko) * 2001-12-28 2004-10-06 선바이오(주) 단백질 의약품 정제 방법에서의 바이러스 제거 방법
US6833238B2 (en) 2002-01-04 2004-12-21 Applera Corporation Petal-array support for use with microplates
ES2261921T3 (es) * 2002-02-20 2006-11-16 MERCK & CO., INC. Procedimiento para determinar la concentracion de particulas de adenovirus.
EP1492890A4 (fr) * 2002-03-29 2006-10-18 Merck & Co Inc Procedes de production a grande echelle d'adenovirus et de collections de semence d'adenovirus
ATE386824T1 (de) * 2002-03-29 2008-03-15 Merck & Co Inc Verfahren zur virusproduktion
ATE360683T1 (de) * 2002-05-14 2007-05-15 Merck & Co Inc Verfahren zur reinigung von adenovirus
US20030224354A1 (en) * 2002-05-30 2003-12-04 Introgen Therapeutics Inc. Quantifying viral particles with intrinsic fluorescence
US20040018559A1 (en) * 2002-07-26 2004-01-29 Applera Corporation Size-exclusion ion-exchange particles
US20040106184A1 (en) * 2002-08-28 2004-06-03 Introgen Therapeutics Inc. Chromatographic methods for adenovirus purification
EP1633321A4 (fr) * 2003-06-18 2006-11-02 Onyx Pharma Inc Procede de purification de virus
ATE500267T1 (de) 2003-07-21 2011-03-15 Transgene Sa Multifunktionelle cytokine
CN101507822B (zh) * 2003-11-24 2012-06-06 坎吉有限公司 皮肤瘢痕形成的减少
EP1697505A1 (fr) * 2003-12-23 2006-09-06 Schering Corporation Methodes servant a preparer des lignees de cellules a549 stables dans un milieu de culture en suspension exempt de serum
SG150501A1 (en) * 2004-02-05 2009-03-30 Millipore Corp Porous adsorptive or chromatographic media
US20060160122A1 (en) * 2004-02-18 2006-07-20 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20050181378A1 (en) * 2004-02-18 2005-08-18 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20050196856A1 (en) * 2004-02-18 2005-09-08 Applera Corporation Polyelectrolyte-coated size-exclusion ion-exchange particles
US20070207461A1 (en) * 2004-02-23 2007-09-06 Crucell Holland B.V. Virus Purification Methods
EP1783138A4 (fr) * 2004-07-27 2007-08-22 Genomidea Inc Procédé de purification d'une enveloppe de virus
AU2005305347A1 (en) * 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
US7851218B2 (en) * 2004-12-13 2010-12-14 Schering Corporation Cell lines for production of replication-defective adenovirus
CA2602944C (fr) * 2005-04-11 2015-08-11 Crucell Holland B.V. Purification de virus faisant appel a une ultrafiltration
EP1736538A1 (fr) 2005-06-21 2006-12-27 Cytos Biotechnology AG Procédé pour la purification préparative de particules pseudo-virales (VLPs)
US7759104B2 (en) * 2005-07-14 2010-07-20 Mayo Foundation For Medical Education And Research Paramyxoviridae virus preparations
DE602006019916D1 (de) * 2005-12-12 2011-03-10 Canji Inc Adenovirale expressionsvektoren mit einer expressionskassette im e1-bereich und einer inaktivierten e2b-polymerase
EP2073849B1 (fr) * 2006-09-29 2010-11-10 CANJI, Inc. Procédés et compositions pour une thérapie génique
CL2008000249A1 (es) 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
US20090130738A1 (en) * 2007-11-19 2009-05-21 Mikhail Kozlov Media for membrane ion exchange chromatography
DK2307551T3 (en) 2008-06-18 2017-03-20 Oxford Biomedica (Uk) Ltd CLEANING RETROVIRAL VECTORS
CA2777837C (fr) * 2008-10-27 2017-07-11 Novartis Ag Procede de purification
US10041049B2 (en) 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
RU2555346C2 (ru) 2009-08-07 2015-07-10 Трансген Са Композиция для лечения инфекции вирусом гепатита в
MX2012007936A (es) 2010-02-15 2012-11-22 Crucell Holland Bv Metodo para la produccion de vectores adenovirales del serotipo 26 del adenovirus.
BR112012026095A2 (pt) 2010-04-14 2015-09-15 Emd Millipore Corp métodos de produção de estoques de vírus de alta pureza e altos títulos e métodos de uso dos mesmos.
US8771709B2 (en) 2010-09-20 2014-07-08 Crucell Holland B.V. Therapeutic vaccination against active Tuberculosis
BR112013004582A2 (pt) 2010-09-27 2016-09-06 Crucell Holland Bv método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
DE102010046817A1 (de) 2010-09-28 2012-03-29 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Viren aus einem Kontaminanten enthaltenden flüssigen Medium
CA2819552C (fr) 2010-12-09 2023-09-26 Institut Pasteur Procede a base de mgmt permettant d'obtenir une expression elevee de proteines recombinees
CN103476399A (zh) 2011-04-18 2013-12-25 独立行政法人国立精神·神经医疗研究中心 药剂递送粒子及其制造方法
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
WO2013045668A2 (fr) 2011-09-29 2013-04-04 Transgene Sa Composition et schéma immunothérapeutique de traitement d'une infection par le virus de l'hépatite c
TW201318637A (zh) 2011-09-29 2013-05-16 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
CN103842501B (zh) * 2011-10-05 2017-12-08 莫尔梅德股份有限公司 病毒载体纯化系统
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SI2825640T1 (sl) 2012-03-12 2016-08-31 Crucell Holland B.V. Šarže rekombinantnega adenovirusa s spremenjenimi konci
US9119813B2 (en) 2012-03-22 2015-09-01 Crucell Holland B.V. Vaccine against RSV
JP5805908B2 (ja) 2012-03-22 2015-11-10 クルセル ホランド ベー ヴェー Ｒｓｖに対するワクチン
CN103571800B (zh) * 2012-07-27 2018-04-24 江苏康润生物科技有限公司 一种去除疫苗中宿主dna的方法
EP3587455A1 (fr) 2012-10-23 2020-01-01 Emory University Conjugués de gm-csf et d'il-4, compositions et procédés associés
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
EP4523756A3 (fr) 2015-02-13 2025-05-28 Transgene Vaccin et polythérapie à base d'anticorps immunothérapeutiques
WO2016131945A1 (fr) 2015-02-20 2016-08-25 Transgene Sa Produit de combinaison modulateur de l'autophagie
JP6735288B2 (ja) 2015-04-14 2020-08-05 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 双方向性プロモーターを有する２つの導入遺伝子を発現する組換えアデノウイルス
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US9663766B2 (en) * 2015-07-24 2017-05-30 Bio-Rad Laboratories, Inc. Methods for purifying adenovirus vectors
IL262108B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
JP7233928B2 (ja) 2016-04-05 2023-03-07 ヤンセン ファッシンズ アンド プリベンション ベーフェー Ｒｓｖに対するワクチン
CA3023022A1 (fr) 2016-05-04 2017-11-09 Transgene Sa Polytherapie avec un ligand de tlr9 cpg
CN109154000B (zh) 2016-05-12 2022-07-05 扬森疫苗与预防公司 有效和平衡的双向启动子
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
RU2745500C2 (ru) 2016-06-20 2021-03-25 Янссен Вэксинс Энд Превеншн Б.В. Эффективный и сбалансированный двунаправленный промотор
WO2018011196A1 (fr) 2016-07-14 2018-01-18 Janssen Vaccines & Prevention B.V. Vaccins contre le hpv
JP7016136B2 (ja) 2016-09-05 2022-02-04 国立研究開発法人科学技術振興機構 病原性微生物検出のための方法及びキット
WO2018069316A2 (fr) 2016-10-10 2018-04-19 Transgene Sa Polythérapie à base d'un produit immunothérapeutique et de modulateurs de mdsc
US11826423B2 (en) 2016-11-16 2023-11-28 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
US11034978B2 (en) 2017-02-09 2021-06-15 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
IL270024B2 (en) 2017-04-22 2025-04-01 Immunomic Therapeutics Inc LAMP structures and their use in vaccination
KR20200016224A (ko) 2017-05-02 2020-02-14 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
AU2018267971A1 (en) 2017-05-17 2019-11-07 Janssen Vaccines & Prevention B.V. Methods and compositions for inducing protective immunity against RSV infection
SG11202001458SA (en) 2017-09-15 2020-03-30 Janssen Vaccines & Prevention Bv Method for the safe induction of immunity against rsv
US11603527B2 (en) * 2017-12-27 2023-03-14 Global Life Sciences Solutions Usa Llc Method and kit for viral vector isolation
JP7329851B2 (ja) * 2018-03-02 2023-08-21 国立研究開発法人科学技術振興機構 酵素反応生成物の検出方法
GB201806736D0 (en) * 2018-04-25 2018-06-06 Ge Healthcare Bioprocess R&D Ab Method for virus purification
EP3793595A1 (fr) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Constructions améliorées de lamp comprenant des allergènes
WO2020061528A1 (fr) 2018-09-21 2020-03-26 University Of Connecticut Compositions et procédés pour restaurer l'expression du gène ube3a paternel dans le syndrome d'angelman humain
JP7233880B2 (ja) * 2018-10-22 2023-03-07 キヤノンメディカルシステムズ株式会社 ウイルスｒｎａ単離方法及びウイルス定量方法
MX2021005607A (es) 2018-11-13 2021-06-30 Janssen Vaccines & Prevention Bv Proteinas f de prefusion del vrs estabilizadas.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
EP3927833A4 (fr) 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. Vecteur adénoviral oncolytique et procédés d'utilisation
JP2022551732A (ja) 2019-10-18 2022-12-13 イミュノミック セラピューティックス， インコーポレイテッド がん抗原を含む改良ｌａｍｐ構築物
CR20220220A (es) 2019-11-18 2022-09-20 Janssen Biotech Inc Vacunas basadas en calr y jak2 mutantes y sus usos
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
WO2021209897A1 (fr) 2020-04-13 2021-10-21 Janssen Biotech, Inc. Vaccins à base de psma et de steap1 et leurs utilisations
US20230035403A1 (en) 2020-07-06 2023-02-02 Janssen Biotech, Inc. Method For Determining Responsiveness To Prostate Cancer Treatment
US20230024133A1 (en) 2020-07-06 2023-01-26 Janssen Biotech, Inc. Prostate Neoantigens And Their Uses
EP4175664A2 (fr) 2020-07-06 2023-05-10 Janssen Biotech, Inc. Néo-antigènes prostatiques et leurs utilisations
JP7526360B2 (ja) * 2020-08-18 2024-07-31 ザルトリウス ビーアイエー セパレーションズ ディー．オー．オー． マルチモーダル金属アフィニティー処理ａａｖカプシド
EP4508071A1 (fr) 2022-04-10 2025-02-19 Immunomic Therapeutics, Inc. Constructions de lamp bicistroniques comprenant des gènes améliorant la réponse immunitaire et leurs procédés d'utilisation
WO2025158316A1 (fr) 2024-01-26 2025-07-31 Janssen Biotech, Inc. Néo-antigènes ovariens et leur utilisation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984004696A1 (fr) * 1983-05-31 1984-12-06 Baxter Travenol Lab Adsorption de particules
US4569794A (en) * 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5447859A (en) * 1993-07-16 1995-09-05 Viagene Method for the purification or removal of retroviruses using sulfated cellulose

Also Published As

Publication number Publication date
EP0813606A2 (fr) 1997-12-29
EP1686180A3 (fr) 2006-08-09
WO1996027677A2 (fr) 1996-09-12
ZA961849B (en) 1997-08-27
DE69636217T2 (de) 2007-04-26
DE69636217D1 (de) 2006-07-20
AU5421396A (en) 1996-09-23
EP0813606B1 (fr) 2006-06-07
ES2264801T3 (es) 2007-01-16
JP2006271396A (ja) 2006-10-12
US5837520A (en) 1998-11-17
PT813606E (pt) 2006-10-31
ATE329045T1 (de) 2006-06-15
JP4182445B2 (ja) 2008-11-19
JP3858200B2 (ja) 2006-12-13
AR001177A1 (es) 1997-09-24
WO1996027677A3 (fr) 1997-01-16
JP2000510682A (ja) 2000-08-22
EP1686180A2 (fr) 2006-08-02

Similar Documents

Publication Publication Date Title
DK0813606T3 (da) Fremgangsmåde til rensning af rekombinante virusvektorer indeholdende et terapeutisk gen
KR100905760B1 (ko) 클론된 뉴클레오타이드 서열로부터 감염성 호흡기세포 융합 바이러스의 생산방법
DK0570916T3 (da) Fremgangsmåde til rensning af humant rekombinant serumalbumin
DK0821690T3 (da) Nukleotidanaloger til behandling af virusinfektioner
PL321966A1 (en) Vaccine against viral hepatitis of b type
DK672788A (da) Rekombinant-dna-vektorer til direkte udtrykkelse af aktiveret humant protein c
PL324906A1 (en) Vaccines against viral hepatitis of c type
DK405286A (da) Anvendelse af dobbeltstrenget rna til behandling af aids
EP1000174A4 (fr) Technique de purification d'acides nucleiques viraux
DK0699687T3 (da) Fremgangsmåde til oprensning af rekombinant humant serumalbumin
NO986202L (no) FremgangsmÕte for fremstilling av rekombinant adÚnovirus
FI945549A7 (fi) Deoksiribonukleaasin puhdistetut muodot
NO952593D0 (no) Fremgangsmåte ved rensing av en glykolopplösning
NO302862B1 (no) Fremgangsmåte for rensing av en gasström
TR199800669A3 (tr) Akrilonitrilin polimerizasyonu için islem
DK0789767T3 (da) Fremgangsmåde til fremstilling af oprensede papilomavirusproteiner
DK0839153T3 (da) Fremgangsmåde til fremstilling af peptider og N-carbamoyl-beskyttede peptider
EP0853629A4 (fr) Recepteur du virus adn de l'hepatite
DE69518743D1 (de) Modifizierung von nukleotidanalogen
KR950702870A (ko) 탈활성 촉매를 재생시키는 개선된 방법(improved method of recenerating deactivated catalyst)
DK0770687T3 (da) Fremgangsmåde til fremstilling af nicotinsyreamid
NO20000575D0 (no) Rekombinant ekspresjon av insulin C-peptid
DK0763100T3 (da) Fremgangsmåde til rensning af Clostridium difficile-texin og fremstilling af monospecifkke antistoffer
DE69621172D1 (de) Trennung von Gasmischungen
IL116973A0 (en) Extraction of recombinant proteins